Biological Therapy During COVID-19
There is crucial question on further therapeutic tactics for the management of such patients (within the severe epidemiological situation caused by the pandemic of new coronavirus SARS-CoV-2) due to widespread application of genetically engineered biologic drugs (GEBD)in management of immune mediated inflammatory diseases. This review sums up current data on the pathogenesis of COVID-19 with the development of acute respiratory distress syndrome associated with cytokine release syndrome (cytokine storm). The effects of GEBD on COVID-19 pathogenesis and their role in management of COVID-19 severe forms of are considered. This review presents the latest guidelines of international associations/consensus and observations of doctors of various specialties on the issue of interruption/continuation of GEBD therapy and with further consequence evaluation in case of interruption of biological therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Вопросы современной педиатрии - 19(2020), 2, Seite 116-122 |
| Sprache: |
Englisch ; Russisch |
|---|
| Beteiligte Personen: |
Leyla S. Namazova-Baranova [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
«цитокиновый шторм» |
|---|
| doi: |
10.15690/vsp.v19i2.2104 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ030543878 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030543878 | ||
| 003 | DE-627 | ||
| 005 | 20230410114743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15690/vsp.v19i2.2104 |2 doi | |
| 035 | |a (DE-627)DOAJ030543878 | ||
| 035 | |a (DE-599)DOAJ4ffecfe12a88463fb3579bcb5536346a | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 050 | 0 | |a RJ1-570 | |
| 100 | 0 | |a Leyla S. Namazova-Baranova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biological Therapy During COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a There is crucial question on further therapeutic tactics for the management of such patients (within the severe epidemiological situation caused by the pandemic of new coronavirus SARS-CoV-2) due to widespread application of genetically engineered biologic drugs (GEBD)in management of immune mediated inflammatory diseases. This review sums up current data on the pathogenesis of COVID-19 with the development of acute respiratory distress syndrome associated with cytokine release syndrome (cytokine storm). The effects of GEBD on COVID-19 pathogenesis and their role in management of COVID-19 severe forms of are considered. This review presents the latest guidelines of international associations/consensus and observations of doctors of various specialties on the issue of interruption/continuation of GEBD therapy and with further consequence evaluation in case of interruption of biological therapy. | ||
| 650 | 4 | |a генно-инженерные биологические препараты | |
| 650 | 4 | |a sars-cov-2 | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a синдром высвобождения цитокинов | |
| 650 | 4 | |a «цитокиновый шторм» | |
| 650 | 4 | |a острый респираторный дистресс-синдром | |
| 650 | 4 | |a tnfα | |
| 650 | 4 | |a il1 | |
| 650 | 4 | |a il6 | |
| 650 | 4 | |a il17 | |
| 650 | 4 | |a il23 | |
| 650 | 4 | |a янус-киназы | |
| 653 | 0 | |a Pediatrics | |
| 700 | 0 | |a Nikolay N. Murashkin |e verfasserin |4 aut | |
| 700 | 0 | |a Roman A. Ivanov |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Вопросы современной педиатрии |d "Paediatrician" Publishers LLC, 2017 |g 19(2020), 2, Seite 116-122 |w (DE-627)DOAJ000055514 |x 16825535 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2020 |g number:2 |g pages:116-122 |
| 856 | 4 | 0 | |u https://doi.org/10.15690/vsp.v19i2.2104 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4ffecfe12a88463fb3579bcb5536346a |z kostenfrei |
| 856 | 4 | 0 | |u https://vsp.spr-journal.ru/jour/article/view/2377 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1682-5527 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1682-5535 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2020 |e 2 |h 116-122 | ||